MGNX vs. BMY
Compare and contrast key facts about MacroGenics, Inc. (MGNX) and Bristol-Myers Squibb Company (BMY).
Performance
MGNX vs. BMY - Performance Comparison
Loading graphics...
MGNX vs. BMY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
MGNX MacroGenics, Inc. | 80.12% | -50.46% | -66.22% | 43.37% | -58.19% | -29.79% | 110.11% | -14.33% | -33.16% | -7.05% |
BMY Bristol-Myers Squibb Company | 15.79% | 0.11% | 15.81% | -26.14% | 18.98% | 2.88% | 0.41% | 27.74% | -12.90% | 7.71% |
Fundamentals
MGNX:
$183.15M
BMY:
$125.99B
MGNX:
-$1.18
BMY:
$3.46
MGNX:
1.23
BMY:
2.61
MGNX:
3.29
BMY:
2.26
MGNX:
$149.50M
BMY:
$48.19B
MGNX:
$0.00
BMY:
$30.43B
MGNX:
-$72.84M
BMY:
$13.82B
Returns By Period
In the year-to-date period, MGNX achieves a 80.12% return, which is significantly higher than BMY's 15.79% return. Over the past 10 years, MGNX has underperformed BMY with an annualized return of -17.13%, while BMY has yielded a comparatively higher 2.90% annualized return.
MGNX
- 1D
- 0.35%
- 1M
- 49.48%
- YTD
- 80.12%
- 6M
- 70.59%
- 1Y
- 137.70%
- 3Y*
- -26.05%
- 5Y*
- -38.23%
- 10Y*
- -17.13%
BMY
- 1D
- 1.78%
- 1M
- -0.98%
- YTD
- 15.79%
- 6M
- 33.50%
- 1Y
- 8.90%
- 3Y*
- 0.70%
- 5Y*
- 3.49%
- 10Y*
- 2.90%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
MGNX vs. BMY — Risk / Return Rank
MGNX
BMY
MGNX vs. BMY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for MacroGenics, Inc. (MGNX) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| MGNX | BMY | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.43 | 0.31 | +1.11 |
Sortino ratioReturn per unit of downside risk | 2.71 | 0.64 | +2.07 |
Omega ratioGain probability vs. loss probability | 1.29 | 1.08 | +0.21 |
Calmar ratioReturn relative to maximum drawdown | 3.76 | 0.25 | +3.51 |
Martin ratioReturn relative to average drawdown | 7.53 | 0.39 | +7.14 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| MGNX | BMY | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.43 | 0.31 | +1.11 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.42 | 0.15 | -0.56 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.15 | 0.12 | -0.26 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.15 | 0.35 | -0.50 |
Correlation
The correlation between MGNX and BMY is 0.25, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
MGNX vs. BMY - Dividend Comparison
MGNX has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 4.03%.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
MGNX MacroGenics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
BMY Bristol-Myers Squibb Company | 4.03% | 4.60% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% |
Drawdowns
MGNX vs. BMY - Drawdown Comparison
The maximum MGNX drawdown since its inception was -97.36%, which is greater than BMY's maximum drawdown of -72.03%. Use the drawdown chart below to compare losses from any high point for MGNX and BMY.
Loading graphics...
Drawdown Indicators
| MGNX | BMY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.36% | -72.03% | -25.33% |
Max Drawdown (1Y)Largest decline over 1 year | -34.16% | -25.79% | -8.37% |
Max Drawdown (5Y)Largest decline over 5 years | -97.02% | -47.67% | -49.35% |
Max Drawdown (10Y)Largest decline over 10 years | -97.02% | -47.67% | -49.35% |
Current DrawdownCurrent decline from peak | -92.79% | -12.07% | -80.72% |
Average DrawdownAverage peak-to-trough decline | -57.90% | -22.40% | -35.50% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 17.04% | 16.06% | +0.98% |
Volatility
MGNX vs. BMY - Volatility Comparison
MacroGenics, Inc. (MGNX) has a higher volatility of 45.24% compared to Bristol-Myers Squibb Company (BMY) at 6.68%. This indicates that MGNX's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| MGNX | BMY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 45.24% | 6.68% | +38.56% |
Volatility (6M)Calculated over the trailing 6-month period | 63.03% | 19.39% | +43.64% |
Volatility (1Y)Calculated over the trailing 1-year period | 97.13% | 28.61% | +68.52% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 92.21% | 23.68% | +68.53% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 115.55% | 25.08% | +90.47% |
Financials
MGNX vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between MacroGenics, Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities